Zobrazeno 1 - 10
of 1 684
pro vyhledávání: '"chimeric antigen receptor-T cell therapy"'
Publikováno v:
Journal of Ovarian Research, Vol 17, Iss 1, Pp 1-21 (2024)
Abstract Ovarian cancer, often referred to as the “silent killer,” is notoriously difficult to detect in its early stages, leading to a poor prognosis for many patients. Diagnosis is often delayed until the cancer has advanced, primarily due to i
Externí odkaz:
https://doaj.org/article/27ce0c22a5cb4ddc8eb5304d7b6146e5
Autor:
Orla McCourt, Paul Maciocia, Claire Roddie, Angela Hwang, Leigh Wood, Aikaterini Panopoulou, Deborah Ann Springell, Maise Al Bakir, Maeve O'Reilly
Publikováno v:
eJHaem, Vol 5, Iss 5, Pp 1033-1037 (2024)
Abstract Introduction This report outlines the evaluation of physiotherapist‐led prehabilitation/rehabilitation for recipients of chimeric antigen receptor T (CAR‐T) cell therapy. Methods A hybrid approach was used, incorporating in‐person asse
Externí odkaz:
https://doaj.org/article/6bd3cfb7d68a4538b79ef361cacaa10c
Publikováno v:
Stem Cell Research & Therapy, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Background Chimeric antigen receptor (CAR)-T therapy has emerged as a promising treatment for hematologic malignancies. However, cytopenia remains one of the most frequent and challenging adverse effects of this therapy. Methods We conducted
Externí odkaz:
https://doaj.org/article/d3c85e66332f47c3b2f0ba5e50178e89
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-4 (2024)
Abstract Multiple classes of therapies targeting claudin-18 isoform 2 (CLDN18.2) are under development for the treatment of advanced gastroesophageal adenocarcinoma and other solid tumors. At the 2024 American Society of Clinical Oncology (ASCO) Annu
Externí odkaz:
https://doaj.org/article/7c852dae49844599adeca9f938191bc2
Publikováno v:
Zhongliu Fangzhi Yanjiu, Vol 51, Iss 8, Pp 648-654 (2024)
Tumor immunotherapy occupies a pivotal position in the field of hematological malignancies. Chimeric antigen receptor (CAR) T-cell therapy has established a new therapeutic pattern for hematological immunotherapy and achieved satisfactory clinical re
Externí odkaz:
https://doaj.org/article/356ab3a80d3b45df983e66a0bbd94215
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-12 (2024)
Abstract Chimeric antigen receptor-T cell therapy, a groundbreaking cancer treatment, has achieved remarkable success against hematologic malignancies. However, CAR-T monotherapy faces challenges in certain cases, including treatment tolerance and re
Externí odkaz:
https://doaj.org/article/f328d036fd1b4482a0a90bd11f67b176
Autor:
Lian-Fang Pu, Hui-Min Zheng, Xiang-Jiang Feng, Alice Charwudzi, Xue Liang, Lin-Hui Hu, Yang-Yang Ding, Ze-Lin Liu, Ya Liao, Shu-Dao Xiong
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Background CD19-targeted chimeric antigen receptor T (CAR-T) cell therapy stands out as a revolutionary intervention, exhibiting remarkable remission rates in patients with refractory/relapsed (R/R) B-cell malignancies. However, the potentia
Externí odkaz:
https://doaj.org/article/e50289f53c6f44b2a90bdaf69002d041
Autor:
WANG Yiyang, LÜ Liangjing
Publikováno v:
Zhenduanxue lilun yu shijian, Vol 23, Iss 03, Pp 263-269 (2024)
Systemic lupus erythematosus (SLE) is a complex autoimmune disease for which traditional treatments often show limited efficacy in severe and refractory cases. Recently, chimeric antigen receptor (CAR) T cell therapy has emerged as a novel immunother
Externí odkaz:
https://doaj.org/article/a2acd7ad8fbe4ed597ea03f34e9dd3a6
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-20 (2024)
Abstract Hematological malignancies (HMs) encompass a diverse group of blood neoplasms with significant morbidity and mortality. Immunotherapy has emerged as a validated and crucial treatment modality for patients with HMs. Despite notable advancemen
Externí odkaz:
https://doaj.org/article/e2f65346268a4085ac837af094ac62af
Autor:
Leyla Sharifi Aliabadi, Mojtaba Azari, Mohammad Reza Taherian, Maryam Barkhordar, Syed Aon Mehdi Abbas, Morteza Azari, Mohammad Ahmadvand, Zahra Salehi, Shiva Rouzbahani, Mohammad Vaezi
Publikováno v:
Virology Journal, Vol 21, Iss 1, Pp 1-22 (2024)
Abstract Background Multiple studies have provided evidence of suboptimal or poor immune responses to SARS-CoV-2 vaccines in recipients of hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor-T (CAR-T) cell therapy compared to
Externí odkaz:
https://doaj.org/article/2acf5a2987a64f35ab0785c281125c2f